Bioequivalence study of Metformin 500 mg tablet
Not Applicable
Recruiting
- Conditions
- In the present study, the products will be administered to healthy volunteers.
- Registration Number
- IRCT20210519051345N51
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (in terms of Liver, Heart and Kidney)
Age (18-59 years)
Exclusion Criteria
Smoking
History of cardiovascular disease, liver and kidney disease
Pregnancy
Alcohol and drug addiction
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of drug. Timepoint: 0.5-24 hours in predetermined time intervals after drug administration. Method of measurement: HPLC (High performance liquid chromatography).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Metformin in glucose regulation and insulin sensitivity?
How does the bioavailability of Fatak Chemie Pars Metformin compare to Glucophage in fasted-state trials?
What biomarkers are associated with Metformin response in type 2 diabetes patients?
What adverse events are commonly reported with Metformin 500 mg tablets in clinical trials?
Are there combination therapies involving Metformin that improve glycemic control in diabetes?